FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2013248985> ?p ?o ?g. }

• W2013248985 endingPage "270" @default.
• W2013248985 startingPage "270" @default.
• W2013248985 abstract "Ionising radiation (IR) can induce immunogenic cell death in tumours, an effect likely to contribute to the success associated with radiotherapy (RT) for cancer. Recent studies suggest that radiotherapy can be applied as a powerful adjuvant to immunotherapy, and can even contribute to converting the irradiated tumour into an in situ vaccine, resulting in specific immunity against metastases [1].Importantly, preclinical models of syngeneic tumours have reliably predicted clinical success in several distinct tumour settings and with several different immunotherapy/radiation combinations. As a proof-of-principle trial, we have translated the preclinical evidence of a successful combination with Flt3 ligand and RT to a protocol of granulocyte–monocyte colony-stimulating factor (GM-CSF) and IR, and demonstrated out-of-field objective responses in 27% of patients with multiple metastases of solid tumours, defined as an abscopal effect [2]In-parallel mechanistic studies in the laboratory were conducted in the syngeneic mouse models of metastatic breast cancer. Results showed that radiation was synergistic with anti-CTLA-4 treatment, a strategy to break immune tolerance to the tumor. Multiple mechanisms contributed to thus synergy, including the RT-induced upregulation of a chemokine that promoted homing of effector T cells to the tumor. Intravital microscopy demonstrated that while both IR and CTLA-4 blockade given as monotherapy enhanced the motility of activated CD8 T cells infiltrating 4T1 tumours, IR with anti-CTLA-4 increased the arrest of T cells in contact with tumour cells, promoting the formation of an immune synapse between cytotoxic T cells and their targets. The latter required interaction between NKG2D on CD8+ T cells and its ligand, retinoic acid early inducible-1 (Rae-1), on the tumour cells, which was up-regulated by IR. Blocking NKG2D–Rae-1 interactions markedly increased the motility of anti-CTLA-4 treated T cells within irradiated tumours, inhibiting their contact with tumour cells and also abrogated immune-mediated tumour rejection [4].The preclinical success of the combination of anti-CTLA-4 antibody and IR was mirrored by abscopal responses seen in metastatic melanoma and non-small-cell lung cancer (NSCLC) patients irradiated in one lesion during ipilimumab therapy. These clinical observations strongly suggest that the effects of IR identified in experimental models are relevant to patients. IR can stimulate the anti-tumor immune response, increasing the proportion of patients who respond to checkpoint blockade treatment, an hypothesis currently being tested in clinical trials. The same pattern of abscopal responses has been observed in preclinical models was also demonstrated in clinical cases of lymphomas and breast cancers treated by combinations of RT and toll-like receptor agonists. Finally, blocking tumour growth factor beta (TGF-beta) during RT preclinically has demonstrated abscopal effects that have been confirmed in one patient accrued to a trial of anti-human TGFb antibody fresolimumab and RT. While promising, this evidence remains preliminary and warrants more research to define the optimal combinations of immunotherapy and RT, to best exploit this novel role of ionising radiation [3]." @default.
• W2013248985 created "2016-06-24" @default.
• W2013248985 creator A5017673781 @default.
• W2013248985 creator A5052554629 @default.
• W2013248985 date "2013-09-01" @default.
• W2013248985 modified "2023-09-26" @default.
• W2013248985 title "Successful clinical translation of preclinical combinations of radiation and immunotherapy" @default.
• W2013248985 cites W2046834643 @default.
• W2013248985 cites W2075879891 @default.
• W2013248985 cites W2133739473 @default.
• W2013248985 cites W2140828776 @default.
• W2013248985 doi "https://doi.org/10.1016/j.ejcsup.2013.07.040" @default.
• W2013248985 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4041317" @default.
• W2013248985 hasPublicationYear "2013" @default.
• W2013248985 type Work @default.
• W2013248985 sameAs 2013248985 @default.
• W2013248985 citedByCount "0" @default.
• W2013248985 crossrefType "journal-article" @default.
• W2013248985 hasAuthorship W2013248985A5017673781 @default.
• W2013248985 hasAuthorship W2013248985A5052554629 @default.
• W2013248985 hasBestOaLocation W20132489851 @default.
• W2013248985 hasConcept C126322002 @default.
• W2013248985 hasConcept C151872237 @default.
• W2013248985 hasConcept C154317977 @default.
• W2013248985 hasConcept C167672396 @default.
• W2013248985 hasConcept C18903297 @default.
• W2013248985 hasConcept C202751555 @default.
• W2013248985 hasConcept C203014093 @default.
• W2013248985 hasConcept C2776090121 @default.
• W2013248985 hasConcept C2777701055 @default.
• W2013248985 hasConcept C2777863537 @default.
• W2013248985 hasConcept C2780674031 @default.
• W2013248985 hasConcept C2781274730 @default.
• W2013248985 hasConcept C502942594 @default.
• W2013248985 hasConcept C509974204 @default.
• W2013248985 hasConcept C55493867 @default.
• W2013248985 hasConcept C71924100 @default.
• W2013248985 hasConcept C82210918 @default.
• W2013248985 hasConcept C86803240 @default.
• W2013248985 hasConcept C8891405 @default.
• W2013248985 hasConceptScore W2013248985C126322002 @default.
• W2013248985 hasConceptScore W2013248985C151872237 @default.
• W2013248985 hasConceptScore W2013248985C154317977 @default.
• W2013248985 hasConceptScore W2013248985C167672396 @default.
• W2013248985 hasConceptScore W2013248985C18903297 @default.
• W2013248985 hasConceptScore W2013248985C202751555 @default.
• W2013248985 hasConceptScore W2013248985C203014093 @default.
• W2013248985 hasConceptScore W2013248985C2776090121 @default.
• W2013248985 hasConceptScore W2013248985C2777701055 @default.
• W2013248985 hasConceptScore W2013248985C2777863537 @default.
• W2013248985 hasConceptScore W2013248985C2780674031 @default.
• W2013248985 hasConceptScore W2013248985C2781274730 @default.
• W2013248985 hasConceptScore W2013248985C502942594 @default.
• W2013248985 hasConceptScore W2013248985C509974204 @default.
• W2013248985 hasConceptScore W2013248985C55493867 @default.
• W2013248985 hasConceptScore W2013248985C71924100 @default.
• W2013248985 hasConceptScore W2013248985C82210918 @default.
• W2013248985 hasConceptScore W2013248985C86803240 @default.
• W2013248985 hasConceptScore W2013248985C8891405 @default.
• W2013248985 hasIssue "2" @default.
• W2013248985 hasLocation W20132489851 @default.
• W2013248985 hasLocation W20132489852 @default.
• W2013248985 hasLocation W20132489853 @default.
• W2013248985 hasOpenAccess W2013248985 @default.
• W2013248985 hasPrimaryLocation W20132489851 @default.
• W2013248985 hasRelatedWork W1483928029 @default.
• W2013248985 hasRelatedWork W2002229753 @default.
• W2013248985 hasRelatedWork W2048095498 @default.
• W2013248985 hasRelatedWork W2103707167 @default.
• W2013248985 hasRelatedWork W2163632499 @default.
• W2013248985 hasRelatedWork W2560230537 @default.
• W2013248985 hasRelatedWork W2595067628 @default.
• W2013248985 hasRelatedWork W2739633277 @default.
• W2013248985 hasRelatedWork W2810177579 @default.
• W2013248985 hasRelatedWork W2810770949 @default.
• W2013248985 hasRelatedWork W287605918 @default.
• W2013248985 hasRelatedWork W2886213129 @default.
• W2013248985 hasRelatedWork W2892023143 @default.
• W2013248985 hasRelatedWork W2896289964 @default.
• W2013248985 hasRelatedWork W2980394375 @default.
• W2013248985 hasRelatedWork W3004296966 @default.
• W2013248985 hasRelatedWork W3043652864 @default.
• W2013248985 hasRelatedWork W3049217352 @default.
• W2013248985 hasRelatedWork W3153841526 @default.
• W2013248985 hasRelatedWork W3176237514 @default.
• W2013248985 hasVolume "11" @default.
• W2013248985 isParatext "false" @default.
• W2013248985 isRetracted "false" @default.
• W2013248985 magId "2013248985" @default.
• W2013248985 workType "article" @default.